Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes

Cellular Physiology and Biochemistry

Volumn 26, Issue 6, 2010, Pages 991-998

  Zhang, Yong ^a,b   Zhang, Li ^a   Chu, Wenfeng ^a,b   Wang, Bing ^a   Zhang, Jialin ^a   Zhao, Mei ^a   Li, Xuelian ^a,b   Li, Baoxin ^a,b   Lu, Yanjie ^a,b   Yang, Baofeng ^a,b   Shan, Hongli ^a,b  

^a Department of Biopharmaceutical Sciences   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cx43; MEF2; miR 1; Myocardial infarction; p38 MAPK; SRF; Tanshinone IIA

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCYTE ENHANCER FACTOR 2; PROTEIN; PROTEIN CX43; PROTEIN MIR 1; TANSHINONE IIA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; ISCHEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

RATTUS;

EID: 78651238069     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324012     Document Type: Article

References (33)

1. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007;13:486-491.
2. 2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyper-phosphorylation of RyR2. Circ Res 2009;104:514-521.
3. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS: Antiischemic effects of SB203580 are mediated through the inhibition of p38{alpha} mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circ Res 2001;89:750-752.
4. Saurin AT, Martin JL, Heads RJ, Foley CLAI, Mockridge JW, Wright MJ, Wang Y, Marber MS: The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J 2000;14:2237-2246.
5. Clerk A, Sugden PH: The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 1998;426:93-96.
6. Gao J, Yang G, Pi R, Li R, Wang P, Zhang H, Le K, Chen S, Liu P: Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res 2008;151:79-87.
7. Shanghai Cooperative Group for the Study of Tanshinone IIA: Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart diseases: a double blind study. J Tradit Clin Med 1984;4:20-24.
8. Li X, Tang RY: Relationship between inhibitory action of tanshinone on neutrophil function and its prophylactic effects on myocardial infarction. Zhongguo Yao Li Xue Bao 1991;12:269-272.
9. Yang R, Liu A, Ma X, Li L, Su D, Liu J: Sodium Tanshinone IIA sulfonate protects cardiomyocytes against oxid-ative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 2008;51:396-401.
10. Shan H, Li X, Pan Z, Zhang L, Cai B, Zhang Y, Xu C, Chu W, Qiao G, Li B, Lu Y, Yang B: Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol 2009;158: 1227-1235.
11. Yang B, Lin H, Xu C, Liu Y, Wang H, Han H, Wang Z: Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac M3 subtype muscarinic acetylcholine receptors. Cell Physiol Biochem 2005;16:163-174.
12. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, Yang B: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007;120:3045-3052.
13. Iliodromitis EK, Gaitanaki C, Lazou A, Aggeli IK, Gizas V, Bofilis E, Zoga A, Beis I, Kremastinos DT: Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioning. Basic Res Cardiol 2006;101:327-335.
14. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, Yoshikawa J: Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 1998;38:116-124.
15. Clerk A, Sugden PH: Inflame my heart (by p38-MAPK). Circ Res 2006;99:455-458.
16. Kloosterman WP, Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 2006;11:441-450.
17. Zhao Y, Ransom JF, Li A, Vedantham V, Von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129:303-317.
18. Matthew J, Potthoff MJ, Olson EN: MEF2: a central regulator of diverse developmental programs. Development 2007;134:4131-4140.
19. Miano JM, Ramanan N, Georger MA, de Mesy Bentley KL, Emerson RL, Balza RO, Jr, Xiao Q, Weiler H, Ginty DD, Misra RP: Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci USA 2004;101:17132-17137.
20. Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, Olson EN: Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 2004; 428:185-189.
21. Black BL, Olson EN: Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 1998; 14:167-196.
22. Molkentin JD, Olson EN: Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci USA 1996;93:9366-9373.
23. Charvet C, Auberger P, Tartare-Deckert S, Bernard A, Deckert M: Vav1 couples T cell receptor to serum response factor-dependent transcription via a MEK-de-pendent pathway. J Biol Chem 2002; 277:15376-15384.
24. Yang SH, Galanis A, Sharrocks AD: Targeting of p38 Mitogen-Activated Protein Kinases to MEF2 Transcription Factors. Mol Cell Biol 1999;19:4028-4038.
25. Zhao M, New L, Kato Y, Gram H, di Padova F, Olson EN, Ulevitch RJ, Han J: Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol 1999;19:21-30.
26. Sugden PH, Clerk A: 'Stress-responsive' mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;83:345-352.
27. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998;273:2161-2168.
28. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, Flavell RA: Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 1999;18:1845-1857.
29. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ: Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci USA 1999;96:3763-3768.
30. Clark JE, Flavell RA, Faircloth ME, Davis RJ, Heads RJ, Marber MS: Post-infarction remodeling is independent of mitogen-activated protein kinase kinase 3 (MKK3). Cardiovasc Res 2007;74:466-470.
31. Kishimoto K, Matsumoto K, Ninomiya-Tsuji J: TAK1 mitogen activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem 2000;275:7359-7364.
32. Li J, Miller EJ, Ninomiya-Tsuji J, Russell III RR, Young LH: AMP activated protein kinase activates p38 mitogen-activated protein kinase by increasing its recruitment to TAB1 in the ischemic heart. Circ Res 2005;97:872-879.
33. Tanno M, Bassi R, Gorog DA, Saurin AT, Jiang J, Heads RJ, Martin JL, Davis RJ, Flavell RA, Marber MS: Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ Res 2003;93:254-261.